AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Elekta

Declaration of Voting Results & Voting Rights Announcements Apr 28, 2017

2906_rns_2017-04-28_a938bd7a-3187-4091-8028-8453b1876ae7.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Number of outstanding shares in Elekta AB

STOCKHOLM, April 28, 2017 – The total number of shares in Elekta as of April 28, 2017, amounts to 383,568,409 divided between 14,980,769 A-shares and 368,587,640 B-shares.

The increase of 730,769 new A-shares and 8,205 new B-shares is attributable to the conversion of shares within the framework of the 2012/17 convertible bond.

One A-share entitles the holder to ten votes and one B-share to one vote.

#

For further information, please contact:

Tobias Bülow, Director Financial Communication, Elekta AB Tel: +46 722 215 017, e-mail: [email protected] Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act The information was submitted for publication at 18:00 CET on April 28, 2017. (REGMAR)

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.